Jubilant Pharmova gets 8 USFDA obervations for Nanjangud facility

Published On 2022-12-15 09:30 GMT   |   Update On 2022-12-15 13:28 GMT

Noida: Jubilant Pharmova Limited has recently announced that the United States Food and Drug Administration (USFDA) has issued eight observations pursuant to the completion of the inspection at the company's API manufacturing facility at Nanjangud, India.The inspection was concluded on December 13, 2022. "The company will submit an action plan on the observations and will engage with US FDA...

Login or Register to read the full article

Noida: Jubilant Pharmova Limited has recently announced that the United States Food and Drug Administration (USFDA) has issued eight observations pursuant to the completion of the inspection at the company's API manufacturing facility at Nanjangud, India.

The inspection was concluded on December 13, 2022. 

"The company will submit an action plan on the observations and will engage with US FDA for next steps," the company stated in a BSE filing.

Read also: Jubilant Generics Roorkee facility determined as official action indicated

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Specialty Pharmaceuticals, Contract Research, Development, and Manufacturing (CRDMO), CDMO, Generics, and Proprietary Novel Drugs businesses. Specialty Pharmaceuticals, CDMO, and Generics businesses through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of radiopharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics/branded formulations through five manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited is also involved in manufacturing of Active Pharmaceutical Ingredients (API) from its USFDA-approved facility in Nanjangud, India. 

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News